Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

SLRX

Salarius Pharmaceuticals Inc

Jan 07 • 03:56PM ET

0.8280

+0.1780 27.38 %

Healthcare • Biotechnology • USA • NASD

Peers: BLRX ADAP AFMD ANAB IMUX EQ AVIR SYBX CLRB

| Held by: MEDX VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-39.23	Insider Own	6.05%	Shs Outstand	6.38M	Perf Week	27.86%
Market Cap	5.29M	Forward P/E	-	EPS next Y	-	Insider Trans	6.90%	Shs Float	6.00M	Perf Month	0.36%
Enterprise Value	0.48M	PEG	-	EPS next Q	-	Inst Own	4.71%	Short Float	3.08%	Perf Quarter	-81.68%
Income	-5.00M	P/S	-	EPS this Y	-	Inst Trans	-0.76%	Short Ratio	0.10	Perf Half Y	-92.70%
Sales	0.00M	P/B	0.18	EPS next Y	-	ROA	-100.54%	Short Interest	0.18M	Perf YTD	27.62%
Book/sh	4.50	P/C	1.10	EPS next 5Y	-	ROE	-139.55%	52W High	108.00 -99.23%	Perf Year	-96.75%
Cash/sh	0.75	P/FCF	-	EPS past 3/5Y	54.55% 57.63%	ROIC	-117.81%	52W Low	0.51 60.84%	Perf 3Y	-99.55%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.79% 9.19%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.08%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	2.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.56	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.79	EPS Q/Q	84.06%	SMA20	18.21%	Beta	0.39	Target Price	390.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-38.90%	Rel Volume	3.22	Prev Close	0.65
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	-88.49%	Avg Volume	1.85M	Price	0.83
IPO	Jan 29, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	5,911,285	Change	27.38%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-20	Initiated	Ladenburg Thalmann	Buy	$3.80

Today 08:45AM	Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics (GlobeNewswire) +27.38%
Dec-19-25 11:12AM	Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (GlobeNewswire)
Dec-18-25 07:50AM	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform (GlobeNewswire)
Dec-01-25 08:00AM	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study (GlobeNewswire) -7.41%
Nov-19-25 02:42PM	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX" (GlobeNewswire) -8.32%
05:35PM	Loading…
Nov-14-25 05:35PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance) -23.41%
Nov-13-25 08:45AM	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger (GlobeNewswire) +5.22%
Nov-11-25 09:18AM	Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering (PR Newswire) -51.00%
Oct-13-25 08:45AM	Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements (GlobeNewswire)
Sep-09-25 08:00AM	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Aug-14-25 08:30AM	Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -6.43%
Aug-12-25 05:35PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -12.04%
Jul-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +34.88%
Jul-14-25 08:30AM	Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard (GlobeNewswire) -9.36%
Jul-09-25 08:30AM	Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies (GlobeNewswire)
05:33PM	Loading…
May-14-25 05:33PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance) +11.53%
Apr-16-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board (GlobeNewswire) -6.71%
Mar-26-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses (GlobeNewswire) -9.78%
Mar-24-25 08:00AM	Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-03-25 08:00AM	Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers (GlobeNewswire)
Jan-13-25 08:00AM	Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement (GlobeNewswire) +134.50%
Nov-14-24 07:25PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Aug-09-24 05:21PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) +11.65% -5.22%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -20.51%
Jun-17-24 08:00AM	Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting (GlobeNewswire)
Jun-12-24 08:00AM	Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split (GlobeNewswire)
May-13-24 10:53PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) -7.12%
04:43PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance)
Mar-22-24 09:52PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) +5.96% -17.74%
04:34PM	Salarius: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-24 08:00AM	Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses (GlobeNewswire)
Jan-16-24 08:00AM	Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Jan-03-24 08:30AM	Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment (GlobeNewswire)
Nov-10-23 05:03AM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Nov-07-23 08:30AM	Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program (GlobeNewswire)
Aug-10-23 05:10PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -9.32% -5.92%
04:05PM	Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-09-23 07:39AM	SLRX Pursuing Strategic Alternatives (Zacks) -9.96%
Aug-08-23 04:05PM	Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources (GlobeNewswire)
Jul-11-23 09:00AM	SLRX Continues Cancer Fight with Phase I Trial Approval (Zacks) -12.41%
08:30AM	Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients (GlobeNewswire)
Jun-12-23 08:00AM	Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress (GlobeNewswire)
May-16-23 04:05PM	Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-12-23 08:00AM	Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-11-23 08:20AM	Salarius: Q1 Earnings Snapshot (AP Finance) -5.41%
08:00AM	Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-09-23 08:00AM	FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma (GlobeNewswire) -16.20%
07:34AM	SLRX: Fighting Cancer Through Two Paths (Zacks Small Cap Research)
May-01-23 08:30AM	Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 (GlobeNewswire)
Apr-20-23 08:30AM	Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting (GlobeNewswire) -10.75%
Apr-04-23 04:02PM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference (GlobeNewswire) -12.32% -5.48%
12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Mar-27-23 08:30AM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-23 11:00AM	Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia (GlobeNewswire)
Feb-16-23 08:30AM	Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas (GlobeNewswire)
Jan-27-23 08:30AM	Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) -5.47%
Jan-19-23 08:30AM	Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) +52.99%
Jan-05-23 08:00AM	Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Dec-13-22 08:01AM	Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire) -5.32%
08:00AM	Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-22 08:00AM	Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH (GlobeNewswire)
Dec-01-22 08:00AM	Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -5.18%
Nov-10-22 08:30AM	Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 09:57AM	Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire)
Oct-27-22 08:30AM	Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -14.40%
Oct-19-22 08:30AM	Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -15.73%
Oct-18-22 08:30AM	Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -45.18%
Oct-14-22 08:43AM	Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -13.81%
Sep-20-22 12:00PM	Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Sep-13-22 08:00AM	Salarius Pharmaceuticals CEO Issues Letter to Stockholders (GlobeNewswire) +10.10%
Aug-22-22 08:30AM	Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -9.29%
Aug-08-22 08:30AM	Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +9.95%
Aug-04-22 08:30AM	Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire)
Aug-02-22 08:30AM	Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement (GlobeNewswire) -6.07%
Jul-29-22 09:15AM	Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022 (GlobeNewswire)
Jun-09-22 07:33AM	Salarius Pharmaceuticals to Participate in BIO International Convention 2022 (GlobeNewswire)
May-18-22 04:10PM	Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +20.62% -9.12%
May-12-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results (GlobeNewswire) +38.75% -15.36%
May-11-22 04:05PM	Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration (GlobeNewswire) -16.93%
May-05-22 07:30AM	Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Apr-22-22 08:30AM	Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering (GlobeNewswire) -20.54%
Mar-10-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results (GlobeNewswire) +33.40% -26.62%
Mar-03-22 07:31AM	Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Feb-17-22 08:01AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference (GlobeNewswire)
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 (GlobeNewswire)
Feb-08-22 08:00AM	Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference (GlobeNewswire)
Feb-03-22 07:30AM	Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program (GlobeNewswire)
Jan-14-22 01:52PM	Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition (American City Business Journals)
Jan-13-22 07:00AM	Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC (GlobeNewswire)
Jan-06-22 12:45PM	Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022" (GlobeNewswire) -6.06%
Dec-29-21 08:03AM	Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial (GlobeNewswire) -6.19%
Dec-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (PR Newswire)
Dec-15-21 08:31AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum (GlobeNewswire)
Dec-14-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live December 16th (PR Newswire)
Nov-29-21 08:01AM	Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference (GlobeNewswire)
Nov-04-21 04:05PM	Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -9.30%
Oct-28-21 03:06PM	Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-26-21 08:01AM	Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress (GlobeNewswire)

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	15	10	5,000	Jan 02 05:13 PM
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	12	8	0	Jan 02 05:13 PM
HANISH ARNOLD C	Director	Nov 20 '25	Buy	0.75	5,000	3,740	5,015	Nov 24 05:08 PM
Rosenblum Mark J	Exec VP Finance, CFO	Nov 20 '25	Buy	0.80	20,000	16,000	20,177	Nov 20 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLRX

Salarius Pharmaceuticals Inc

Upgrade your FINVIZ experience